Table 1.
Study Comparison
| Study ID | Types of participants | Number of treatment groups | Type of trabeculoplasty | Degree of laser | Comparison (baseline IOP in mmHg) |
|---|---|---|---|---|---|
| Barnebey 1993 | Uncontrolled glaucoma | 4 | ALT | 360 | Brimonidine before and after vs brimonidine before and vehicle after vs vehicle before and brimonidine after vs vehicle before and after (individual baseline IOPs not reported; range 23.4 ± 0.6 to 24. 3 ± 0.7) |
| Barnes 1999 | POAG, pigmentary glaucoma, pseudoexfoliation syndrome, or ocular hypertension | 2 | ALT | 360 | Brimonidine (19.6 ± 4. 5) vs apraclonidine (20.5 ± 4. 6) |
| Birt 1995 | POAG | 3 | ALT | 180 | Apraclonidine before and after (22.2 ± 3.6) vs apraclonidine before (23.9 ± 5.3) vs apraclonidine after (22. 1 ± 3.2) |
| Brown 1988 | Inadequately controlled IOP despite maximum-tolerated medical therapy | 2 | ALT | 360 | Apraclonidine before and after vs placebo before and after (IOPs not available) |
| Carassa 1992 | Advanced glaucoma on maximal tolerated medical therapy with inadequate IOP control | 2 | Apraclonidine before and after (19.20 ± 5.95) vs placebo before and after (19.80 ± 5.23) |
||
| Chevrier 1999 | Candidates for ALT, peripheral iridectomy, or posterior capsulotomy | 2 | ALT | 180 | Brimonidine before (20.3 ± 6) vs apraclonidine before (20.0 ± 5.1) *the reported IOPs included participants who received other types of glaucoma surgery besides ALT |
| Dapling 1994 | OAG | 3 (1 combination group not of interest in this study) | ALT | 180 | Apraclonidine before and after vs pilocarpine after (“all eyes had...an IOP greater than 21mmHg”) |
| David 1993 | Participants undergoing ALT | 4 | ALT | 360 | Brimonidine before and after (23.3) vs brimonidine before, placebo after (23.9) vs placebo before, brimonidine after (24.1) vs placebo before and after (24.0) |
| Donnelly 2006 | POAG | 2 (opposite eyes) | SLT | 360 | Brimonidine before vs apraclonidine after (right eyes: 18, left eyes: 18.4) |
| Elsas 1991 | Exfoliative glaucoma and simple glaucoma | 2 | ALT | 360 | Pilocarpine before (34.9 ± 8.1) vs no treatment (33.3 ± 5. 6) |
| Hartenbaum 1999 | OAG requiring ALT | 2 | ALT | 180 | Dorzolamide before and after (18.3 ± 0.57) vs placebo before and after (19.6 ± 0.72) |
| Holmwood 1992 | OAG | 2 | ALT | 360 | Apraclonidine before and after (22.6 ± 0.9) vs apraclonidine after (22. 6 ± 0.6) |
| Karlik 1997 | Glaucoma | 2 | ALT | 180 | Latanoprost before (24. 1) vs apraclonidine before (23.2) |
| Karlik 1998 | Glaucoma | 2 | ALT | 180 | Latanoprost before vs apraclonidine before |
| Kitazawa 1990 | POAG | 2 | ALT | 180 | Apraclonidine before and after (24.2 ± 9.0) vs placebo before and after (23.2 ± 6.8) |
| Ma 1999 | Glaucoma | 4 | ALT | 180 | Brimonidine before and after (24.9) vs brimonidine before, placebo after (24.8) vs placebo before, brimonidine after (24.1) vs placebo before and after (24.6) |
| Metcalfe 1989 | Uncontrolled OAG | 2 | ALT | 180 | Acetazolamide before (23.6 ± 6.1) vs placebo before (23.7 ± 6.5) |
| Raspiller 1992 | POAG | 2 | ALT | 360 | ALO 2145 (apraclonidine) before and after (20.1 ± 4.07) vs placebo before and after (25.0 ± 5.47) |
| Ren 1999 | POAG | 2 | ALT | 180 | Apraclonidine before (23.2 ± 4.5) vs pilocarpine before (21.7 ± 3.5) |
| Robin 1987 | OAG | 2 | ALT | 360 | ALO 2145 (apraclonidine) before and after (26.4 ± 3.0) vs placebo before and after (27.9 ± 6.9) |
| Robin 1991 | OAG with disc and visual field damage | 5 | ALT | 360 | Apraclonidine before and after (27.2 ± 5.1) vs timolol before and after (27.6 ± 4.1) vs pilocarpine before and after (27.1 ± 5.1) vs dipivefrin before and after (25.9 ± 3.0) vs acetazolamide before and after (25.7 ± 3.9) |
| Yalvaç 1996 | POAG | 3 | ALT | 360 and 180 | Apraclonidine before and after, 180° ALT (26.1 ± 5.1) vs placebo before and after, 180° ALT (25.6 ± 3.4) vs apraclonidine before and after, 360° ALT (26.4 ± 3.1) |
ALT: argon laser trabeculoplasty; IOP: intraocular pressure; OAG: open-angle glaucoma; POAG: primary open-angle glaucoma; SLT: selective laser trabeculoplasty.